Diabetic Macular Edema (DME) Market Report for M&A, Expansion and Competitive Benchmarking (2025–2034)
This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Diabetic Macular Edema (DME) industry.
What is the anticipated market size of the diabetic macular edema (dme) industry over the next few years?
The diabetic macular edema (DME) market size has grown steadily in recent years. It will grow from $4.67 billion in 2024 to $4.89 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rise in prevalence of diabetes, increase in edema-related disorders, growth in prevalence of diabetic eye diseases, surge in geriatric population, and increase cases of blindness.
The diabetic macular edema (DME) market size is expected to see steady growth in the next few years. It will grow to $5.82 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to increasing healthcare access, rising government healthcare funding, rising awareness about diabetic complications, growing adoption of telemedicine for eye care, and expansion of specialized diabetic eye care centers. Major trends in the forecast period include development of anti-VEGF therapies, adoption of corticosteroid implants, advancements in drug delivery systems, innovation in retinal laser treatments, AI-powered diagnostic tools, and adoption of minimally invasive surgical techniques.
Download Your Free Sample PDF:
What emerging drivers are expected to shape the future of the diabetic macular edema (dme) market?
The increase in prevalence of diabetes is expected to drive the growth of the diabetic macular edema (DME) market going forward. The increasing prevalence of diabetes is attributed to factors such as sedentary lifestyles, unhealthy dietary habits, rising obesity rates, aging populations, and genetic predisposition. Diabetes causes diabetic macular edema by damaging retinal blood vessels, leading to leakage of fluid into the macula and resulting in swelling. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people globally were living with diabetes. This number is expected to more than double, reaching 1.3 billion people by 2050. Therefore, the increase in prevalence of diabetes is driving the growth of the diabetic macular edema (DME) market.
What emerging segments are shaping the future landscape of the diabetic macular edema (dme) industry?
The diabetic macular edema (DME) market covered in this report is segmented –
1) By Treatment: Anti-VEGF Therapy, Corticosteroids, Laser Therapy, Surgical Intervention
2) By Disease Stage: Early Stage, Moderate Stage, Advanced Stage
3) By Patient Demographics: Adults, Elderly, Children
4) By Route Of Administration: Intravitreal Injection, Topical, Systemic
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Anti-VEGF Therapy: Monoclonal Antibodies, Recombinant Protein-Based Therapies
2) By Corticosteroids: Intravitreal Steroid Injections, Injectable Sustained-Release Corticosteroids
3) By Laser Therapy: Focal Laser Photocoagulation, Panretinal Photocoagulation
4) By Surgical Intervention: Vitrectomy, Membrane Peeling
View The Full Market Report:
How are emerging trends transforming the diabetic macular edema (dme) market dynamics?
Major companies operating in the diabetic macular edema (DME) treatment market are focusing on technological advancements, such as advanced drug therapies, to improve the management and treatment outcomes for patients. Advanced drug therapies are innovative treatments that use new technologies and research to better treat complex health conditions. These therapies focus on improving effectiveness, reducing side effects, and offering better outcomes for patients. For instance, in March 2022, Novartis AG, a Switzerland-based pharmaceutical company, announced the European Commission's approval of Beovu for treating visual impairment due to diabetic macular edema (DME). The approval was based on Phase III KESTREL and KITE study results, demonstrating Beovu's comparable effectiveness to aflibercept in improving vision after one year. Notably, over half of the Beovu-treated patients maintained a 12-week treatment schedule, with fewer instances of retinal fluid compared to aflibercept.
How are key players in the diabetic macular edema (dme) market strengthening their market position?
Major companies operating in the diabetic macular edema (DME) market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Carl Zeiss Meditec AG, Bausch & Lomb, Santen Pharmaceutical Co. Ltd., Carl Zeiss AG, Topcon Corporation, Ypsomed AG, ARKRAY Inc, Hugel Inc., Optos plc, Noven Pharmaceuticals Inc., Alimera Sciences Inc., Allergan plc.
Which geographic areas are contributing significantly to the growth of the diabetic macular edema (dme) sector?
North America was the largest region in the diabetic macular edema (DME) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic macular edema (DME) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Diabetic Macular Edema (DME) Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Diabetic Macular Edema (DME) Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment